A Study of Donanemab (LY3002813) in Participants With Preclinical Alzheimer’s Disease (TRAILBLAZER-ALZ 3)
GPTKB entity
Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:ageRange |
60-85 years
|
| gptkbp:allocates |
Randomized
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:clinicalTrials.govIdentifier |
NCT05026866
|
| gptkbp:conditionStudied |
Preclinical Alzheimer’s Disease
|
| gptkbp:enrollment |
3300
|
| gptkbp:estimatedCompletionDate |
December 2027
|
| https://www.w3.org/2000/01/rdf-schema#label |
A Study of Donanemab (LY3002813) in Participants With Preclinical Alzheimer’s Disease (TRAILBLAZER-ALZ 3)
|
| gptkbp:intervention |
Donanemab (LY3002813)
|
| gptkbp:location |
International (multiple countries)
|
| gptkbp:mask |
Double-blind
|
| gptkbp:otherName |
TRAILBLAZER-ALZ 3
|
| gptkbp:purpose |
Prevention
|
| gptkbp:sponsor |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:startDate |
September 2021
|
| gptkbp:status |
Recruiting
|
| gptkbp:studyType |
Interventional
|
| gptkbp:bfsParent |
gptkb:NCT05240898
|
| gptkbp:bfsLayer |
7
|